SUTRO BIOPHARMA, INC. Form EFFECT: Notice of effectiveness
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-04-01: Form EFFECT; Description Notice of effectiveness; Document xslEFFECTX01/primary_doc.xml.
- 2023-11-21: Form EFFECT; Description Notice of effectiveness; Document xslEFFECTX01/primary_doc.xml.
- 2022-05-19: Form EFFECT; Description Notice of effectiveness; Document xslEFFECTX01/primary_doc.xml.
- 2019-10-11: Form EFFECT; Description Notice of effectiveness; Document xslEFFECTX01/primary_doc.xml.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-04-01 | EFFECT | Notice of effectiveness | xslEFFECTX01/primary_doc.xml | |
| 2023-11-21 | EFFECT | Notice of effectiveness | xslEFFECTX01/primary_doc.xml | |
| 2022-05-19 | EFFECT | Notice of effectiveness | xslEFFECTX01/primary_doc.xml | |
| 2019-10-11 | EFFECT | Notice of effectiveness | xslEFFECTX01/primary_doc.xml | |
| 2018-09-26 | EFFECT | Notice of effectiveness | xslEFFECTX01/primary_doc.xml |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |